Alere Receives IVD CE Marking In Europe For Q HIV-1/2 Detect Assay - Quick Facts

(RTTNews) - Alere Inc. (ALR) announced it has received IVD CE marking in Europe for the Alere q HIV-1/2 Detect assay, the first molecular diagnostic at the point of care that identifies HIV-1 and HIV-2 in less than 60 minutes.

"Accurate and timely diagnosis and access to anti-retroviral therapy is a matter of life or death for infants. In the absence of HIV testing and timely initiation of ART, one third of infants living with HIV die before their first birthday and half die before the age of two years. Before the development of the Alere q technology, early infant testing could only be performed in centralized labs with long lead times, delaying results and the initiation of critical treatment for children," said, Avi Pelossof, Alere Global President of Infectious Disease.

With the availability of Alere q HIV-1/2 Detect, Alere broadens its offering of diagnostic solutions for the complete continuum of HIV care from initial screening and diagnosis to staging and ongoing monitoring.